id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-D-3632-0002,FDA,FDA-2018-D-3632,Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment; Guidance for Industry; Draft Guidance,Other,Guidance,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,,2024-11-12T22:50:30Z,,1,0,090000648393a073
FDA-2018-D-3632-0001,FDA,FDA-2018-D-3632,Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,2019-02-05T04:59:59Z,2024-11-12T22:50:44Z,2018-26333,1,0,09000064839394fb